MedTrace Logo

Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS

NCT03996434 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-11-21

No results posted yet for this study

Summary

The aim of this work is to study the value of GnRH antagonist subcutaneous administration as an alternative to coasting in prevention of severe OHSS and its impact on embryos quality \& the outcome of ICSI.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Gonadotropin

withholding gonadotropin administration for at least 24 hours

DRUG

Antagonist

Cetrorelix acetate 0.25 mg

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • Al-Azhar University

    collaborator OTHER

  • Beni-Suef University

    collaborator OTHER

  • ClinAmygate

    lead OTHER

Principal Investigators

  • Eman Elgendy, MD · International Islamic Centre for Population Studies and Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2019-11-10
Completion
2019-11-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03996434 on ClinicalTrials.gov